Navigation Links
International Vaccine Institute announces launch of Dengue Vaccine Initiative
Date:2/10/2011

SEOUL, KOREA, Feb. 10The International Vaccine Institute (IVI) today announced the launch of the Dengue Vaccine Initiative (DVI), in collaboration with the Sabin Vaccine Institute (Sabin), the Johns Hopkins University (JHU), and the World Health Organization (WHO), to support development of vaccines to control dengue fever, a widespread and expanding hemorrhagic fever that is endemic in most tropical and subtropical regions of the world.

Through a $6.9 million grant from the Bill & Melinda Gates Foundation, DVI will accelerate the development and utilization of safe, affordable and broadly protective vaccines to combat dengue, a mosquito-borne infection which causes severe flu-like symptoms, and its potentially lethal complication dengue hemorrhagic fever, characterized by bleeding, plasma fluid leakage, and in severe cases shock and death. Each year, an estimated 2 million people with dengue hemorrhagic fever require hospitalization representing a significant burden on the fragile healthcare systems of developing and endemic nations.

"We are extremely grateful for the Gates Foundation's continued support of our critical work to promote the development of life-saving dengue vaccines and ensure their effective introduction. Dengue is an infection whose burden has increased sharply around the world," said Dr. John Clemens, Director-General of IVI. "The global dengue community is on the eve of many important breakthroughs in dengue research and development, and I believe that we'll make significant progress in controlling dengue within the decade."

An estimated 3.6 billion individuals (55% of the world's population) are at risk of contracting dengue, an infection caused by four distinct, yet closely related viruses. Recovery from one strain of dengue confers lifelong immunity against the infecting strain but increases the risk for development of hemorrhagic fever, shock, and death following infection from the other three strains.

"Development and use of a dengue vaccine represents the best hope of preventing cases, deaths and economic losses," said Dr. Ciro de Quadros, Executive Vice President of Sabin. "There are very few places that dengue does not impact. The infection is endemic in more than 100 countries across the globe and incidence of infection in typically unexpected places is increasingly common."

Current methods are limited to vector control, which have been largely ineffective at controlling dengue with the number of cases and geographic reach of the infection increasing dramatically each year. According to the WHO, the incidence of dengue has increased 30-fold over the last 50 years with 50 million dengue infections now occurring worldwide each year.

To contribute to raising the priority and support for new dengue vaccines likely to be licensed in a few years, DVI will undertake concentrated work in two countriesColombia and Thailandto generate data on the burden of disease, potential private demand, cost of illness and seroprevalence of dengue infection. In addition, DVI will carry out private demand and cost of illness studies in Brazil and Vietnam.

"Dengue is high on the agenda of many countries, so are the expectations into a dengue vaccine," said Dr. Joachim Hombach, Acting Head of WHO's Initiative for Vaccine Research. "Activities conducted under DVI will not only promote the development of safe and effective vaccines but ensure that products will be accessible and affordable to impoverished communities where the infection is endemic."

"In many cases, insufficient planning and financing for new vaccines has significantly slowed uptake in countries that need them most" said Dr. Orin Levine, Executive Director, International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. "At IVAC, we look forward to overcoming the economic obstacles to dengue vaccine use as part of DVI and to paving the way for rapid uptake of vaccines as early as 2015."


'/>"/>

Contact: Eteena Tadjiogueu
eteena@sabin.org
202-265-6517
Sabin Vaccine Institute
Source:Eurekalert

Related medicine news :

1. BUSM researchers involved in first international collaboration on genetics of Alzheimers disease
2. 3rd international conference on innovative approaches in head and neck oncology
3. Lung societies unveil new international classification of lung adenocarcinoma
4. American Chemical Society unveils International Year of Chemistry virtual journal
5. International community called upon to stop the runaway train of cancer in Africa
6. Biodesign hosts international consortium on screening for lung cancer
7. Pier Paolo Pandolfi, M.D., Ph.D., to receive Pezcoller-AACR International Award for Cancer Research
8. International research team reports major findings in prevention and treatment of blood clots
9. International consortium to examine the impact of medical devices on health and retirement
10. New international conference in bionic engineering
11. International clinical trial tests targeted drug for melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... 2016 , ... Healthcare is in flux. The GOP wants ... mass media launching of story movements to highlight what's most unfair about healthcare. ... such a movement can generate the network power to improve healthcare policies in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is ... by smoothing and tightening the skin of the face to create more youthful ... aging with very little downtime, Silhouette Instalift is a novel, minimally invasive facial ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
(Date:12/8/2016)... -- Mederi Therapeutics Inc . hat die behördliche Zulassung durch die ... Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the ... at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: